Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uro-Vaxom molecular mechanism pilot study in premenopausal women with recurrent urinary tract infection
2013-004961-14Phase 4Completed
- Sponsor
- Kliniken Kärnan Urology Centre
- Start
- Apr 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of OM-89 in urinary tract infection (UTI), sponsored by Kliniken Kärnan Urology Centre. Primary endpoint: Gene expression analysis based on whole genome transcriptomics. Started Apr 2014; status: completed.
02
Drugs
OM-89
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on 2013-004961-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004961-14.